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Introduction
Obsessive Compulsive Disorder (OCD) is a neuropsychiatric disorder which 
often proves refractory to current treatment approaches, New treatment 
options are needed to improve health outcomes1. Brain imaging 
demonstrates abnormal cortico-striatal neurocircuitry as underlying OCD 
pathology and a target for neurostimulation2.
Transcranial Direct Current Stimulation (tDCS), a non-invasive form of 
neurostimulation, with potential for development as a self-administered 
intervention, has shown potential as a safe and efficacious treatment for 
OCD in a small number of RCTs and uncontrolled studies3.  The two most 
promising stimulation sites are located above the orbitofrontal cortex (OFC) 
and the supplementary motor area (SMA). 
From our feasibility study of tDCS in OCD3, results on acceptability, safety of 
the intervention, feasibility of recruitment, adherence and tolerability are 
presented in this poster.
Due to COVID-19 this study was paused in March 2020 and restarted in July 
2020, consequently facing the challenges of recruiting and continuing face-
to-face research during the pandemic. 
Methods
• A double-blind, sham-controlled, cross-over randomised multicentre  
feasibility study in adults with non treatment-resistant OCD
• Potential participants were identified from OCD clinics, primary health 
care services (e.g. IAPTs), charity/support networks, advertisements 
and trust databases across two sites (Hertfordshire and Southampton)
• Individuals were screened, eligible participants received three courses 
of tDCS (SMA, OFC and sham/placebo ), randomly allocated and given 
in counterbalanced order
• Each course comprised four sessions of 20-minute stimulations, 2 mA, 
cathodal, delivered over two consecutive days, separated by at least a 
four-week washout period
• Participants were evaluated using validated scales, by raters blinded to 
treatment allocation, at baseline, 1, 2 and 4 hours after stimulation
• Follow-up assessments were conducted via telephone at 24 hours, 7 
and 14 days following the last stimulation of each round with a final 
assessment 28 days after the third round
• Intervention-related adverse events (AEs) were recorded at each time 
point, using a questionnaire specific to tDCS4
Results 
A total of 135 individuals were identified as potentially eligible (through 
clinics or self-referral), of which 36 consented to eligibility screening. Four 
withdrew consent/were lost to follow up, so screening was completed for 
32. Subsequently, 12 were excluded through ineligibility (n=9), withdrawal 
(n=2) or loss to follow up (n=1), with the remaining 20 randomised. Two 
participants withdrew prior to intervention both due to COVID-19 anxiety. 
All other participants (n=18, 90% of those randomised) completed all 
intervention rounds. 
Across all tDCS sessions, the most commonly reported AEs were sleepiness 
(18.7% of sessions), trouble concentrating (13.0%) and headache (12.2%), 
with other AE types present at <7% of sessions (Table 1). For some AEs 
there is a relative higher reported number in the OFC treatment sessions 
compared to SMA and Sham, although severity was low.
Participant comments represented strong positivity and acceptability of the 
feasibility study (Figure 1).
Discussion
Despite the impact of COVID-19, this study successfully restarted after 
suspension with few adjustments, meeting the revised target sample with 
minimal participant drop-out. Reasons for drop-out were unrelated to the 
intervention itself, with some participants delayed or experiencing 
pandemic-related anxiety. Our study confirms tDCS a safe intervention 
which was accepted, adhered to and tolerated well by OCD patients, even 
amid a pandemic.
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TABLE 1: ADVERSE EVENTS
FIGURE 1: PARTICIPANTS COMMENTS
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“I felt like I achieved something which was really 
empowering for me”
“Looking forward to coming into the clinic gave 
some purpose and particularly through lockdown 
was lovely to spend time with people ”
“it has changed the way that I think and has 
really improved my life”
Type of Adverse Event (n %) n
Treatment Condition
OFC SMA Sham
Sleepiness 166 (18.7%) 53 (18%) 53 (17.6%) 60 (20.3%)
Trouble Concentrating 116 (13.0%) 46 (15.6%) 29 (9.6%) 41 (13.9%)
Headache 109 (12.2%) 33 (11.2%) 41 (13.6%) 35 (11.9%)
Acute Mood Change 58 (6.5%) 27 (9.2%) 12 (4%) 19 (6.4%)
Skin Redness 50 (5.6%) 34 (11.6%) 14 (4.7%) 2 (0.7%)
Other 48 (5.4%) 28 (9.5%) 10 (3.3%) 10 (3.4%)
Tingling 37 (4.2%) 15 (5.1%) 16 (5.3%) 6 (2%)
Neck Pain 24 (2.7%) 12 (4.1%) 8 (2.7%) 4 (1.4%)
Burning Sensation 21 (2.4%) 12 (4.1%) 8 (2.7%) 1 (0.3%)
Scalp Pain 9 (1.0%) 4 (1.4%) 5 (1.7%) 0 (0%)
Itching 7 (0.8%) 1 (0.3%) 1 (0.3%) 5 (1.7%)
Total 645 265 197 183
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